• Follow-up of Patients With Curative-intent Surgical Resection for NSCLC

  NCT00199615

  CompletedInterventionalNot ApplicableUpdated Jul 30, 2025
• FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy

  NCT00424138

  TerminatedInterventionalNot ApplicableUpdated Oct 11, 2018
• Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy

  NCT03740126

  CompletedInterventionalNot ApplicableUpdated Aug 17, 2026
• Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

  NCT01507428

  CompletedInterventionalPhase 2Updated Apr 21, 2026
• Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

  NCT00083083

  Unknown statusInterventionalPhase 2Updated Mar 1, 2011
• Positron Emission Tomography for Detecting Non-small Cell Lung Cancer

  NCT00004138

  CompletedInterventionalNot ApplicableUpdated Jul 13, 2016

ClinicalTrials.gov ID

NCT06082492

Lead Sponsor

Radboud University Medical CenterOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

690Estimated

Last Update Posted

Feb 5, 2025Actual

Start Date

Mar 19, 2024Actual

Primary Completion Date

Apr 2029Estimated

Completion Date

Jun 2029Estimated

Official Title

The Beneficial Value of 18F FDG PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients: the NVALT31-PET Study

Brief Summary

The primary objective of this study is to compare the 3-year overall survival of stage III NSCLC patients during follow-up surveillance with 18F-Fluorodeoxyglucose Positron Emission Tomography/ Computerized Tomography (18F FDG PET/CT) versus follow-up with conventional CT surveillance.

Participants will receive usual care until 3 years of follow-up (control group) with additional whole-body 18F FDG PET/CT scans during follow-up visits at 6 months, 12 months, 18 months, 24 months, and 36 months of follow-up in the intervention group.

Other tasks include:

• filling in quality of life (QOL) questionnaires at every time point;
• participating in an interview evaluating the addition of the 18F FDG PET/CT scans (optional);
• collecting blood at the follow-up time points for our secondary endpoint (optional).

Researchers will compare the usual care control group with the intervention group to see if the additional 18F FDG PET/CT scans are (cost-)effective.

Detailed Description

Stage III non-small cell lung cancer (NSCLC) patients are at high risk of developing recurrences (50-78%) during follow-up. With more effective treatments available for patients with oligometastatic disease, early detection of tumor recurrence can prolong survival and health-related quality of life and thereby lower the disease burden. With the use of 18F FDG PET/CT during follow-up, recurrences may be detected earlier at an oligometastatic state when curative-intent treatment is still possible.

Primary objective:

- The primary objective of this study is to compare the 3-year overall survival of stage III NSCLC patients during follow-up surveillance with 18F FDG PET/CT versus follow-up with conventional CT surveillance.

The secondary objectives of this study are:

• To compare the 2-year overall survival of stage III NSCLC patients during follow-up surveillance with 18F FDG PET/CT versus follow-up with conventional CT-based surveillance (interim analysis);
• To compare the number of detected (symptomatic and asymptomatic) recurrences of stage III NSCLC patients during follow-up surveillance with 18F FDG PET/CT versus follow-up with conventional CT-based surveillance;
• To compare the event-free survival of stage III NSCLC patients during follow-up surveillance with 18F FDG PET/CT versus follow-up with conventional CT-based surveillance;
• To determine the cost-effectiveness of 18F FDG PET/CT versus conventional CT-based surveillance during follow-up of stage III NSCLC patients;
• To compare the effect of 18F FDG PET/CT versus conventional CT-based surveillance on health-related quality of life during follow-up of stage III NSCLC patients;
• To assess the beneficial value of ctDNA in the detection of recurrences during follow-up in stage III NSCLC patients;
• To identify patients' experiences with the additional 18F FDG PET/CT scans in the follow-up of stage III NSCLC patients.
• To assess differences in type of treatment following recurrence during follow-up in stage III NSCLC patients.

Primary analyses will be performed on an intention-to-treat basis as well as per protocol. Kaplan-Meier curves with stratified log-rank 2-sided tests will be used to compare the survival between groups. In case of empty strata, strata will be collapsed. The clinical relevance of the difference will be primarily expressed in terms of 3-year survival of the intervention versus the control group.

• Stage III Non-small Cell Lung Cancer

• 18F FDG PET/CT
• CT scan

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Eligible for this study are patients with stage III NSCLC (8th edition TNM Classification) who (are about to) start(ed) follow-up care (which may include adjuvant treatment) at a participating hospital. Patients may already be included during their curative intent treatment. Patients enter a screening period that runs until their randomization.

Inclusion Criteria:

To be eligible to participate in this study, a subject must meet all of the following criteria at the timing of randomization:

• Cytological or histologically proven stage III non-small cell lung cancer before start of curative intent treatment
• Treated with curative intent and started follow-up care
• All adjuvant treatments are permitted as co-intervention during follow-up care
• Age 18 years or older
• ECOG Performance Status classification 0-2 at moment of inclusion
• Written and signed informed consent by the patient or patient's representative (with the understanding that consent may be withdrawn by the patient or patient's representative at any time without consequences to future medical care)

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

• Life expectancy shorter than 6 months at the end of curative intent treatment
• Evidence of recurrence after end of curative intent treatment and before randomization (4 months follow-up)
• Any condition that, in the opinion of the investigator, would interfere with evaluation of the intervention or interpretation of HRQOL or other study results.

Primary Purpose

Diagnostic

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Radboud University Medical CenterOTHER

Collaborators

Amsterdam UMC, location VUmcOTHER

Streekziekenhuis Koningin BeatrixUNKNOWN

Canisius-Wilhelmina HospitalOTHER

Diakonessenhuis, UtrechtOTHER

Dijklander ZiekenhuisOTHER

Deventer ZiekenhuisOTHER

Elisabeth-TweeSteden ZiekenhuisOTHER

Gelre HospitalsOTHER

Groene Hart ZiekenhuisOTHER

HagaZiekenhuisOTHER

Martini Hospital GroningenOTHER

Medisch Spectrum TwenteOTHER

St. Antonius HospitalOTHER

Franciscus &VlietlandOTHER

TjongerschansUNKNOWN

MaasstadziekenhuisUNKNOWN

Gelderse Vallei HospitalOTHER

Bravis HospitalOTHER

Tergooi HospitalOTHER

Treant ZorggroepUNKNOWN

Amphia HospitalOTHER

UMC UtrechtOTHER

OLVGNETWORK

Haaglanden Medical CentreOTHER

Antoni van Leeuwenhoek HospitalOTHER

research-longgeneeskunde@olvg.nl